Pharma: Protecting Research IP and Patient Data in Email

A world-leading pharmaceutical company had to protect years of research IP and patient-linked clinical data in the same channel: email.

ISE classifies compound data, synthesis routes, clinical protocols, trial records and PII without manual labeling, then decides on each message based on content, sender, recipient and context. Approved collaborators keep working; misdirected dossiers, encrypted-attachment bypass, bulk transfers and uploads to external GenAI tools are stopped.

The case study walks through the eight email risk vectors, the five protection capabilities and how one deployment addresses five regulatory frameworks.